Analysts Are Bullish on These Healthcare Stocks: Enovis (ENOV), BioCryst (BCRX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Enovis (ENOV – Research Report) and BioCryst (BCRX – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Enovis (ENOV)
In a report released today, Michael Matson from Needham reiterated a Buy rating on Enovis, with a price target of $52.00. The company’s shares closed last Thursday at $25.42.
According to TipRanks.com, Matson is a 2-star analyst with an average return of
Currently, the analyst consensus on Enovis is a Strong Buy with an average price target of $45.20.
See today’s best-performing stocks on TipRanks >>
BioCryst (BCRX)
According to TipRanks.com, Belanger is a 5-star analyst with an average return of
Currently, the analyst consensus on BioCryst is a Strong Buy with an average price target of $21.50, representing a 162.4% upside. In a report issued on February 18, Evercore ISI also resumed coverage with a Buy rating on the stock with a $17.00 price target.
